Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech Invests in Unity Biotech's $116 Million Series B

publication date: Oct 28, 2016
WuXi PharmaTech, the China-US CRO/CMO, participated in the $116 million Series B funding of Unity Biotechnology. Unity, a San Francisco biotech, is developing therapies that eliminate senescent cells from the body. The company has identified molecules that target aging diseases such as osteoarthritis, glaucoma and atherosclerosis. Unity is 18 months away from a Phase I trial that tests a candidate for treatment of arthritis of the knee. According to BioCentury, Unity's Series B is the 12th-largest it has seen in 22 years. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital